
Wen-Chien Chou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8602027/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. Bone Marrow Transplantation, 2022, 57, 95-105.	2.4	8
2	Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015. Annals of Hematology, 2022, 101, 109-118.	1.8	1
3	Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Annals of Hematology, 2022, 101, 349-358.	1.8	12
4	Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair. Oncogene, 2022, 41, 1576-1588.	5.9	3
5	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal, 2022, 12, .	6.2	23
6	The expression levels of long nonâ€coding RNA <i>KIAA0125</i> are associated with distinct clinical and biological features in myelodysplastic syndromes. British Journal of Haematology, 2021, 192, 589-598.	2.5	5
7	Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. Annals of Hematology, 2021, 100, 487-498.	1.8	19
8	Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Advances, 2021, 5, 2456-2466.	5.2	31
9	Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients. Journal of the Formosan Medical Association, 2021, 121, 643-643.	1.7	1
10	Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. British Journal of Haematology, 2021, , .	2.5	2
11	PDâ€L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients. Journal of Pathology: Clinical Research, 2021, , .	3.0	2
12	A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. Blood Advances, 2021, 5, 4535-4548.	5.2	19
13	<i>RUNX1</i> Expression Can be Complementary to <i>RUNX1</i> Mutation in MDS Prognostication. Blood, 2021, 138, 2614-2614.	1.4	0
14	Metabolic Profiling Reveals Cellular Reprogramming of Acute Myeloid Leukemia By Omipalisib through Serine Synthesis Pathway. Blood, 2021, 138, 3296-3296.	1.4	2
15	Epidemiology of Light-Chain Amyloidosis: A Population-Based Cohort Study in Taiwan. Blood, 2021, 138, 1637-1637.	1.4	3
16	Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed <i>FLT3</i> -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. Blood, 2021, 138, 700-700.	1.4	18
17	ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. Blood Cancer Journal, 2020, 10, 99.	6.2	5
18	Knock-out of Hopx disrupts stemness and quiescence of hematopoietic stem cells in mice. Oncogene, 2020, 39, 5112-5123.	5.9	22

#	Article	IF	CITATIONS
19	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Annals of Hematology, 2020, 99, 501-511.	1.8	52
20	A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Advances, 2020, 4, 644-654.	5.2	14
21	Accurate Prediction of Gene Mutations with Flow Cytometry Immune-Phenotyping By Machine Learning Algorithm. Blood, 2020, 136, 7-8.	1.4	2
22	Prognostic Prediction with Static-Dynamic Clinical and Pathological Parameters By Machine Learning Algorithm in Acute Lymphoblastic Leukemia. Blood, 2020, 136, 1-1.	1.4	0
23	Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry. Blood, 2020, 136, 6-8.	1.4	1
24	Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. International Journal of Hematology, 2019, 110, 411-418.	1.6	9
25	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. New England Journal of Medicine, 2019, 381, 1728-1740.	27.0	796
26	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. EBioMedicine, 2019, 40, 240-250.	6.1	23
27	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2019, 19, 617.	2.6	43
28	Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. British Journal of Haematology, 2019, 186, 72-85.	2.5	11
29	Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials. Blood Advances, 2019, 3, 2355-2367.	5.2	30
30	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood, 2019, 133, 1140-1151.	1.4	96
31	Automatic Bone Marrow Cell Identification and Classification By Deep Neural Network. Blood, 2019, 134, 2084-2084.	1.4	20
32	The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia. Blood, 2019, 134, 2705-2705.	1.4	0
33	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer Journal, 2018, 8, 39.	6.2	68
34	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poorâ€risk factor in <i>de novo</i> acute myeloid leukemia patients. European Journal of Haematology, 2018, 101, 86-94.	2.2	31
35	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics, 2018, 10, 42.	4.1	36
36	Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine, 2018, 37, 91-100.	6.1	54

#	Article	IF	CITATIONS
37	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. Blood Cancer Journal, 2018, 8, 87.	6.2	34
38	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . Haematologica, 2018, 103, e510-e513.	3.5	29
39	Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterology, 2018, 18, 6.	2.0	20
40	The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome. Blood Cancer Journal, 2018, 8, 78.	6.2	23
41	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	3.0	20
42	Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Standard Chemoimmunotherapy. Blood, 2018, 132, 4235-4235.	1.4	0
43	Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA. Cancer Research, 2017, 77, 494-508.	0.9	41
44	Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higherâ€risk myelodysplastic syndromes. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e430-e439.	1.1	4
45	Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in <i>de novo</i> acute myeloid leukemia. Haematologica, 2017, 102, 1044-1053.	3.5	35
46	Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer Journal, 2017, 7, 663.	6.2	39
47	The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model. Journal of Hematology and Oncology, 2017, 10, 139.	17.0	40
48	A 4-IncRNA scoring system for prognostication of adult myelodysplastic syndromes. Blood Advances, 2017, 1, 1505-1516.	5.2	19
49	Germline variations at <i>JAK2</i> , <i>TERT</i> , <i>HBS1L-MYB</i> and <i>MECOM</i> and the risk of myeloproliferative neoplasms in Taiwanese population. Oncotarget, 2017, 8, 76204-76213.	1.8	11
50	High expression of <i>dedicator of cytokinesis 1</i> (<i>DOCK1</i>) confers poor prognosis in acute myeloid leukemia. Oncotarget, 2017, 8, 72250-72259.	1.8	20
51	A three-gene expression-based risk score can refine the European LeukemiaNet AML classification. Journal of Hematology and Oncology, 2016, 9, 78.	17.0	21
52	Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. Scientific Reports, 2016, 6, 36730.	3.3	18
53	Characteristics of Taiwanese patients of PNH in the international PNH registry. Thrombosis Journal, 2016, 14, 39.	2.1	4
54	The Clinical and Biological Effects of the Expression of Dedicator of Cytokinesis 1 (DOCK1) in Acute Myeloid Leukemia. Blood, 2016, 128, 1695-1695.	1.4	1

#	Article	IF	CITATIONS
55	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget, 2016, 7, 63177-63188.	1.8	21
56	Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia. Oncotarget, 2016, 7, 9084-9101.	1.8	77
57	Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 49-49.	1.4	0
58	The Clinical and Biological Effects of Expression of Dedicator of Cytokinesis 1 (DOCK1) in Myelodysplastic Syndrome. Blood, 2016, 128, 5517-5517.	1.4	0
59	The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL). Blood, 2016, 128, 2860-2860.	1.4	0
60	A 6-Lncrna Scoring System for Prognostication of Adult Myelodysplastic Syndromes. Blood, 2016, 128, 4344-4344.	1.4	0
61	Overexpression of Calr Mutants Perturbs Developmental Hematopoiesis in Zebrafish Embryos. Blood, 2016, 128, 4282-4282.	1.4	0
62	Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0119831.	2.5	6
63	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0126037.	2.5	21
64	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. PLoS ONE, 2015, 10, e0137552.	2.5	7
65	Clinical characteristics and treatment outcomes of patients with candidaemia due to <i>Candida parapsilosis sensu lato</i> species at a medical centre in Taiwan, 2000–12. Journal of Antimicrobial Chemotherapy, 2015, 70, 1531-1538.	3.0	21
66	GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. Annals of Hematology, 2015, 94, 211-221.	1.8	23
67	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS ONE, 2015, 10, e0128410.	2.5	50
68	Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer, 2015, 15, 344.	2.6	48
69	Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clinica Chimica Acta, 2015, 440, 133-139.	1.1	19
70	An mRNA expression signature for prognostication in <i>de novo</i> acute myeloid leukemia patients with normal karyotype. Oncotarget, 2015, 6, 39098-39110.	1.8	42
71	The Clinical and Biological Characterization of De Novo Acute Myeloid Leukemia (AML) with GATA2 Mutation. Blood, 2015, 126, 3822-3822.	1.4	0
72	Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 4956-4956.	1.4	0

#	Article	IF	CITATIONS
73	B Cell Immune Profiles in Essential Thrombocythemia with Calr Mutations: Clinical and Molecular Correlates. Blood, 2015, 126, 1610-1610.	1.4	0
74	IPSSâ€R in 555 <scp>Taiwanese</scp> patients with primary MDS: Integration of monosomal karyotype can better riskâ€stratify the patients. American Journal of Hematology, 2014, 89, E142-9.	4.1	16
75	<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i> , <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution. American Journal of Hematology, 2014, 89, 137-144.	4.1	76
76	Clinical implications of the <i>SETBP1</i> mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2014, 89, 181-186.	4.1	56
77	Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Annals of Hematology, 2014, 93, 1371-1380.	1.8	54
78	Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leukemia Research, 2014, 38, 1278-1284.	0.8	22
79	<i>SF3B1</i> mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution. American Journal of Hematology, 2014, 89, E109-15.	4.1	34
80	The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. Haematologica, 2014, 99, 1799-1807.	3.5	13
81	A Simple, Powerful, and Widely Applicable Micro-RNA Scoring System in Prognostication of De Novo Myeloid Leukemia Patients. Blood, 2014, 124, 71-71.	1.4	1
82	Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. BMC Cancer, 2013, 13, 107.	2.6	11
83	Higher <i>lipocalin 2</i> expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1614-1625.	1.3	21
84	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East. Annals of Hematology, 2013, 92, 799-806.	1.8	14
85	Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10. Journal of Antimicrobial Chemotherapy, 2013, 68, 2632-2635.	3.0	24
86	Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2013, 88, E277-82.	4.1	56
87	Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood, 2013, 121, 3172-3180.	1.4	58
88	Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia. PLoS ONE, 2013, 8, e60624.	2.5	48
89	Gfi-1 is the transcriptional repressor of <i>SOCS1</i> in acute myeloid leukemia cells. Journal of Leukocyte Biology, 2013, 95, 105-115.	3.3	17
90	The Role Of tet2 DNA Methylcytosine Dioxygenase In Zebrafish Early Hematopoiesis. Blood, 2013, 122, 1204-1204.	1.4	0

#	Article	IF	CITATIONS
91	The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood, 2012, 120, 3106-3111.	1.4	127
92	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 2670-2677.	1.6	998
93	Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001–2010. International Journal of Antimicrobial Agents, 2012, 40, 533-538.	2.5	30
94	A Knock-In Npm1 Mutation in Mice Results in Myeloproliferation and Implies a Perturbation in Hematopoietic Microenvironment. PLoS ONE, 2012, 7, e49769.	2.5	21
95	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 2012, 119, 559-568.	1.4	211
96	Rapid Assessment of the Heterogeneous Methylation Status of CEBPA in Patients with Acute Myeloid Leukemia by Using High-Resolution Melting Profile. Journal of Molecular Diagnostics, 2011, 13, 514-519.	2.8	13
97	Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia. , 2011, , .		1
98	The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia, 2011, 25, 246-253.	7.2	150
99	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 2011, 118, 3803-3810.	1.4	272
100	Dynamic Contrast-enhanced MR Imaging Measurement of Vertebral Bone Marrow Perfusion May Be Indicator of Outcome of Acute Myeloid Leukemia Patients in Remission. Radiology, 2011, 258, 821-831.	7.3	44
101	DNMT3A Mutations in Acute Myeloid Leukemia-Stability During Disease Evolution and the Clinical Implication. Blood, 2011, 118, 409-409.	1.4	23
102	Quantitative Monitoring of EBV Viral Load in 222 Hematopoietic Stem Cell Transplant Patients: Risk Analysis and Development of EBV-Associated Post-Transplant Lymphoproliferative Diseases (PTLD). Blood, 2011, 118, 3018-3018.	1.4	0
103	A "canonical―Npm1 mutation Knock-in Mouse Model Revealed Subtle but Definitive Myeloid Expansion with Poor HSC Niche Interaction. Blood, 2011, 118, 762-762.	1.4	Ο
104	Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica, 2010, 95, 1420-1424.	3.5	17
105	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115, 2749-2754.	1.4	193
106	WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood, 2010, 115, 5222-5231.	1.4	156
107	A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations. Blood, 2010, 116, 495-496.	1.4	12
108	Psoas Abscess Caused by Non-Typhoid <i>Salmonella</i> in a Patient with Severe Aplastic Anemia. Yonsei Medical Journal, 2010, 51, 472.	2.2	4

#	Article	IF	CITATIONS
109	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 2010, 116, 4086-4094.	1.4	187
110	Bone Marrow Hypoplasia Induced by Conditional Knockout of the RNase III Domain of Dicer-1. Blood, 2010, 116, 2226-2226.	1.4	0
111	Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood, 2009, 113, 3161-3167.	1.4	75
112	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood, 2009, 114, 5352-5361.	1.4	318
113	AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations Blood, 2009, 114, 1564-1564.	1.4	3
114	CEBPA Methylation as a Prognostic Biomarker in Adult Patients with De Novo AML Blood, 2009, 114, 1569-1569.	1.4	0
115	Role of Gene Mutations in Adult Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 3373-3373.	1.4	0
116	Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leukemia Research, 2008, 32, 904-912.	0.8	55
117	Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. British Journal of Haematology, 2008, 141, 736-739.	2.5	12
118	Clinical and Biological Characterization of Adult Patients with Acute Myeloid Leukemia Bearing T(7;11)(p15;p15)—Analysis of 536 Patients. Blood, 2008, 112, 2535-2535.	1.4	1
119	Hierarchical Cluster Analysis of Immunophenotype in AML Patients with NPM1 Gene Mutation Reveals Two Distinct Groups with Different Prognosis Blood, 2008, 112, 1495-1495.	1.4	0
120	Methylation Status of miRNA Let-7a-3 in Acute Myeloid Leukemia. Blood, 2008, 112, 4482-4482.	1.4	0
121	Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica, 2007, 92, 141-142.	3.5	39
122	<i>RUNX1</i> gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. British Journal of Haematology, 2007, 139, 405-414.	2.5	122
123	Characterization of Acute Myeloid Leukemia with PTPN11 Mutation - The Mutation Is Closely Associated with NPM1 Mutation but Inversely Related to FLT3/ITD Blood, 2007, 110, 3490-3490.	1.4	2
124	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. British Journal of Haematology, 2006, 135, 317-323.	2.5	32
125	<i>Nucleophosmin</i> Mutations in <i>De novo</i> Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. Cancer Research, 2006, 66, 3310-3316.	0.9	165
126	Quantitative Assessment of Minimal Residual Disease Predicts Outcome of Patients of Acute Myeloid Leukemia with Nucleophosmin (NPM) Mutation Blood, 2006, 108, 561-561.	1.4	6

Wen-Chien Chou

#	Article	IF	CITATIONS
127	Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Current Opinion in Hematology, 2005, 12, 1-6.	2.5	74
128	Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood, 2005, 106, 304-310.	1.4	74
129	Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4578-4583.	7.1	207
130	Arsenic inhibition of telomerase transcription leads to genetic instability. Journal of Clinical Investigation, 2001, 108, 1541-1547.	8.2	101
131	Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. British Journal of Haematology, 1998, 103, 1092-1095.	2.5	120
132	Clonal disease of natural killer large granular lymphocytes in Taiwan. British Journal of Haematology, 1998, 103, 1124-1128.	2.5	14
133	Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13-Cis retinoic acid. , 1996, 78, 1805-1812.		35
134	Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Kiâ€1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13â€Cis retinoic acid. Cancer, 1996, 78, 1805-1812.	4.1	3
135	Hypovolemic shock and mortality after ingestion of Tripterygium wilfordii hook F.: a case report. International Journal of Cardiology, 1995, 49, 173-177.	1.7	64